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Abstract
Purpose Surveillance CT colonography (CTC) is a viable op-
tion for 6-9 mmpolyps at CTC screening for colorectal cancer.
We established participation and diagnostic yield of surveil-
lance and determined overall yield of CTC screening.
Material and methods In an invitational CTC screening trial
82 of 982 participants harboured 6-9 mm polyps as the largest
lesion(s) for which surveillance CTC was advised. Only par-
ticipants with one or more lesion(s) ≥6 mm at surveillance
CTC were offered colonoscopy (OC); 13 had undergone pre-
liminary OC. The surveillance CTC yield was defined as the
number of participants with advanced neoplasia in the 82 sur-
veillance participants, and was added to the primary screening
yield.
Results Sixty-five of 82 participants were eligible for surveil-
lance CTC of which 56 (86.2 %) participated. Advanced neo-
plasia was diagnosed in 15/56 participants (26.8 %) and 9/13
(69.2 %) with preliminary OC. Total surveillance yield was
24/82 (29.3 %). No carcinomas were detected. Adding sur-
veillance results to initial screening CTC yield significantly
increased the advanced neoplasia yield per 100 CTC partici-
pants (6.1 to 8.6; p<0.001) and per 100 invitees (2.1 to 2.9; p
<0.001).
Conclusion Surveillance CTC for 6-9 mm polyps has a sub-
stantial yield of advanced adenomas and significantly in-
creased the CTC yield in population screening.
Key Points
• The participation rate in surveillance CT colonography
(CTC) is 86 %.
• Advanced adenoma prevalence in a 6-9 mm CTC surveil-
lance population is high.
• Surveillance CTC significantly increases the yield of popu-
lation screening by CTC.
• Surveillance CTC for 6-9 mm polyps is a safe strategy.
• Surveillance CTC is unlikely to yield new important
extracolonic findings.
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Introduction
Colorectal cancer (CRC) screening with computed tomography
colonography (CTC) is aimed at detecting individuals with CRC
and significant polyps (advanced neoplasia). As the size of a
polyp correlates with advanced histology, for CTC this selection
is based on lesion size [1]. Large polyps (≥10 mm) should be
removed by polypectomy and diminutive lesions (<6 mm) can
be ignored. Debate remains regarding the management of small
(6-9 mm) polyps [2]. Despite the low probability of harbouring
advanced histology (3 %–6.6 % in an asymptomatic primary
screening population) [1, 3], European and US colorectal cancer
screening guidelines advise to refer all patients with ≥6 mm
polyps for optical colonoscopy (OC), a policy that is primarily
based on expert opinion until further evidence is available [4–6].
Surveillance CTCmight be a viable alternative, but there is great
need for data on CTC surveillance studies to determine the
strength of a CTC surveillance strategy [7, 8].
Recently, a population-based screening trial was performed
in which the participation rate and yield of OC and CTC as
primary CRC screening modalities were compared in 8844
invitees after randomisation (COCOS trial) [8]. It was shown
that with higher participation in the CTC group, and higher
yield in the OC group, CTC and OC have similar yields for
advanced neoplasia per invitee. However, in that trial only
CTC participants with lesions ≥10 mm were referred for
OC. CTC participants with a largest lesion ranged between
6-9 mmwere recommended for a surveillance CTC. The yield
of this surveillance population might give further direction to
the discussion about the management of patients with small
polyps. In addition, a provisional yield of CTC screening was
reported [8]. For a definite yield of screening with CTC, the
yield of surveillance CTC should be included.
We performed a prospective surveillance study in those
individuals with only small (6-9 mm) polyps in the aforemen-
tioned trial. We determined the yield of surveillance CTC for
advanced neoplasia as well as the total yield of CTC screening
in the COCOS trial. In addition, the surveillance participation
rate and the number of new relevant (E3 or E4) extracolonic
findings were determined [9].
Material and methods
Study design
In a previous randomized controlled trial (RCT) participation
and diagnostic yield of OC and CTC in an invitational
population-based screening program of individuals aged 50-
75 years was compared [8]. The overall design of the trial has
been described in detail previously [10]. In that population
screening trial 2920 out of 8844 trial invitees individuals were
invited for CTC (others for OC) of which 982 participated
(Fig. 1). All participants with only polyps measuring 6-
9 mm (n=82) were advised to undergo a surveillance CTC
after 1.5 or 3 years (with ≥3 or <3 polyps, respectively).
This trial was registered in the Dutch Trial Register
(NTR3549). Ethics approval from the Dutch Health Council
(2009/03WBO, The Hague, the Netherlands) was obtained for
this trial, including surveillance CTC. Patients had already
given their written informed consent to be contacted for
follow-up studies and consented to this study.
Participants
Patients were contacted by postal mail. Patients with surveil-
lance advice who were willing to undergo surveillance CTC
were included, unless they underwent a CTC or OC in the
time between the initial screening CTC and their invitation
for surveillance CTC. In that case, findings of those examina-
tions were requested and included in the yield analysis.
Medical history and medication use were documented.
CTC
CTC scan protocol, preparation, and reading strategy were
deliberately kept identical to the initial CTC [8]. The prepara-
tion consisted of two times 50 mL of iodinated contrast agent
(Telebrix Gastro, Guerbet, Aulnaysous-Bois, France) on the
day before the examination [11]. Another 50 mL was given
1.5 hour prior to the examination (total 150 mL) and a low-
fibre diet was followed for one day. Colonic distention was
obtained by automatic carbon dioxide insufflation
(PROTOCO2L, Bracco, EZEM, Lake Success, NY, USA)
after intravenous 20 mg hyoscine butylbromide (if contraindi-
cated, 1 mg glucagon hydrochloride intravenously). Supine
and prone position CT images were obtained on two 64-slice
CT scanners (Brilliance, Philips Healthcare, Best, the
Netherlands; SOMATOM Sensation, Siemens Medical
Solutions, Erlangen, Germany, with 64 x 0.625 mm detec-
tor-rows, slice thickness 0.9 mm, reconstruction interval
0.7 mm, tube voltage 120 kV, and 25 reference mAs (for
Brilliance) and 128 x 0.6 mm detector-rows, slice thickness
1.0 mm, reconstruction interval 0.7 mm, tube voltage 120 kV,
and 16 reference mAs (for SOMATOM Sensation).
All CTCs were evaluated within two weeks after the exam
by one experienced abdominal radiologist (CYN, abdominal
radiologist since 19 years, 14 years of CTC experience includ-
ing approximately 2000 CTCs) as this reading strategy was
also used for the COCOS trial. Images were read in primary
2D (window setting 1500, -250 HU) with 3D read (supine and
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prone) for problem solving. Following this strategy, a second-
ary computer-aided detection (CAD) reading was performed
using a commercial CAD system (ColonCAD, Philips
Healthcare). The observer was not blinded to the findings of
the initial COCOS CTC and performed polyp matching [12].
Maximum linear diameter, morphology (flat, sessile, pedun-
culated or tumour) and location (caecum, ascending, trans-
verse, descending, sigmoid or rectum) were noted.
Extracolonic organs and findings were examined by one of
two radiologists using the C-RADS classification [CYN and
MT (MT, abdominal radiologist since 14 years)] [9].
For the sole purpose of determining definite polyp regres-
sion, the surveillance CTCs were retrospectively also evaluat-
ed by two of four experienced readers. We did not use their
evaluations for yield calculations.
Follow-up after a positive test result
OC was indicated for all participants with at least one polyp
measuring ≥6 mm at surveillance CTC. Polyps smaller than
6 mm were ignored because of the very low prevalence of
malignancy in these lesions [1, 13].
Approximately ten weeks after a positive surveillance
CTC, an OC was performed by experienced endoscopists
(see Appendix 1) [14]. Segmental unblinding of CTC findings
was performed by a research nurse or research fellow.
Detected lesions were described and removed for histopatho-
logical examination. Lesions were classified by two expert
gastrointestinal pathologists (same as in initial trial, MVDV
and KB as hyperplastic polyp, serrated adenoma, adenoma or
carcinoma (Vienna classification) [15]. Advanced adenoma
was defined as an adenoma that is ≥10 mm and/or has more
than 25 % villous component and/or high grade dysplasia
[16]. For determination of lesion size, measurements at OC
were used. Advanced neoplasia was defined as either an ad-
vanced adenoma or invasive colorectal cancer. As serrated
adenomas ≥10 mmwere not classified as advanced adenomas
in the original COCOS trial, we described them separately.
Statistical analysis
Descriptive analysis of patients, polyps and extracolonic find-
ings were presented. Participation rate was defined as the
number of participants undergoing the surveillance CTC rel-
ative to the total number of patients invited to undergo sur-
veillance CTC. Diagnostic surveillance yield was defined as
the number of patients with an advanced neoplasia in our
surveillance population of 82 patients, which was a combined
Fig. 1 Participation and outcome
of CTC patients in the COCOS
trial including surveillance CTC.
ahad OC prior to surveillance
invitation, OC findings were used
for our analyses. b2 refused
(repeat) OC, 1 is still to be
performed. AA=advanced
adenoma, CRC=colorectal
cancer
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yield of individuals that underwent surveillance CTC and of
individuals that underwent a preliminary OC.
The overall diagnostic yield of CTC in the population-
based trial was defined as the number of patients detected with
advanced neoplasia relative to all participants and relative to
all invitees of the initial trial. A McNemar test for paired
observations (in 982 participants and in 2920 invitees) was
used to calculate differences between initial yield and overall
yield including surveillance CTC. The P-values less than 0.05
were deemed significant.
The scope of this paper was not to present an in-depth per-
polyp analyses with change in size during the surveillance
interval, as within the framework of CTC screening for CRC
the per-patient results are considered the primary end-point.
We used SPSS forWindows, version 19, for all the analyses.
Results
Participation
Between February 2011 and May 2014 the 82 individuals
(mean age 66.0 (SD 6.8); 56 % (46/82) male) with 6-9 mm
polyps at initial screening CTC were approached for surveil-
lance CTC (Fig. 1). Of these, four individuals died (Table 1).
Thirteen underwent OC prior to invitation (Table 1), seven of
which because they participated in a study parallel to the initial
trial on the optimal reading strategy for CTC, comparing the
yield of a radiologist to that of two radiologic technologists
(n=7) [17]. In these seven individuals OC was performed
because one of the technologists measured the polyp as
≥10 mm, in contrast to the radiologist measurement of 6-
9 mm. We did use the OC findings of those 13 individuals
with a preliminary OC for our yield calculations. In total, 65 of
82 individuals were invited, of which 56 (86.2 %) participated
in surveillance CTC (all non-participation reasons are summa-
rized in table 1). Mean surveillance interval was 3.4 years (SD
0.43; range 2.0-4.6). All three individuals with 1.5-year sur-
veillance advice were excluded (one died and two were cop-
ing with another illness).
Yield of surveillance CTC
At CTC surveillance, in 17 patients were no polyps detected and
in three patients only a <6 mm polyp was detected. These 20
(36%) of 56 participants required therefore no further follow-up
examinations. After retrospective evaluation of these 17 surveil-
lance CTCs with no polyps by two experienced readers, polyp
regression was suggested in ten patients (Appendix 2). Thirty-
six (64 %) of 56 participants had polyps ≥6 mm, of which 24
with 6-9mmpolyps and 12with at least one ≥10mmpolyp, and
were referred for OC. All referrals were based on polyps corre-
sponding to the 6-9mmpolyps on the initial CTC.Until now, 34
of 36 participants underwent anOC,mean time interval between
CTC and OC of 10.7 weeks (SD 6.2; range 3.4-25.3). Two
patients refused OC, and in one patient OC was stopped prior
to completion due to a large number of polyps that required
removal, and the participant refused repeat OC (because of con-
comitant health problems) (Table 1). In these three participants
the polyp was detected at CTC was therefore not removed. In
one participant no lesions were detected during OC.
Of all 56 patients participating in surveillance CTC, 15
(26.8 %) had advanced adenomas (Fig. 1). No colorectal can-
cers were detected. The positive predictive value (PPV) for
advanced neoplasia of surveillance CTC on a per-patient level
was 45 % (15/33) (95 % CI 0.15-0.76). The PPV for matched
polyps on a per-patient level, regardless of histology, was
97 % (32/33) (95 % CI 0.91-1.03). Included was the use of
Table 1 Reasons for non-
participation in surveillance CTC
or in the advised OC after a
positive test result
Reason Surveillance CTC OC
Died* 4 ─
I have undergone a colonoscopy since the initial CTC
because of referral advise in context of CTC reading
strategy study [17]
7 ─
because of worries about the presence of polyps detected
at primary screening CTC
4 ─
because of bowel related complaints 2 ─
I am coping with another illness 5 2
I am too old ─ 1
After a negative FIT I see no reason to participate 1 ─
General physician does not think it is necessary and I agree 1 ─
Own contribution of insurance policy is too high 1 ─
Non-respondence 1 ─
Total number of non-participants 26 3
*2 of lung cancer, 1 of complicated perforated diverticulitis, 1 unknown cause
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CAD, which had resulted in one additional OC with an ad-
vanced neoplasia.
Yield of preliminary OC
In 13 individuals with an OC prior to invitation, mean time
between index CTC and preliminary OC was 54.0 weeks (SD
43.8, range 3.9-137.0) (see for a detailed timeframeAppendix 3).
Of these, nine had advanced adenomas (in all seven indivi-
duals referred for OC based on technologists advise, in one
because of bowel complaints and in one because of worries
about the presence of small polyps) (Fig. 1).
Yield of entire surveillance population
The per-patient yield for advanced neoplasia of our total sur-
veillance population was 29.3 (24/82). Tables 2 and 3 sum-
marize the characteristics of all detected adenomas and serrat-
ed lesions (see also Appendix 4). In total, 32 advanced ade-
nomas were detected, of which 29 (91%)were at least 10mm,
11 (34 %) contained 25 % or more a villous component and
none contained high-grade dysplasia. The other 117 neoplas-
tic lesions included 100 tubular adenomas and 17 serrated
lesions. Two patients had a large (5 and 3.5 cm) rectal carpet
lesion at OC. One was under surveillance for this lesion which
measured 6-9 mm at the initial CTC; OC and polypectomy
revealed a sessile polyp with tubular histology. The other had
undergone an OC prior to invitation (because of complaints)
showing a carpet (flat) lesion with tubulovillous histology,
which was not noted on the initial CTC (interval lesion).
Overall yield of screening with CTC
At initial screening, 60 CTC participants were found with at
least one advanced neoplasia out of all 982 CTC participants
Table 2 Characteristics of 32
advanced adenomas Resulting from
surveillance CTC
Resulting from
preliminary OC
Size
≥10 mm 19 (90 %) 10 (91 %)
6-9 mm 2 (10 %) 1 (9 %)
<6 mm 0 0
Histology
Villous 0 1 (9 %)
Tubulovillous 6 (29 %) 4 (36 %)
Tubular 15 (71 %) 6 (55 %)
Dysplasia
High-grade dysplasia 0 0
Low-grade dysplasia 21 (100 %) 11 (100 %)
Total 21 11
Table 3 Morphology and location of detected adenomas and serrated
lesions
Morphology of detected adenomas
Advanced adenomas 32
Flat 5 (16 %)
Sessile 13 (41 %)
Pedunculated 13 (41 %)
Missing 1 (3 %)
Non-advanced adenomas 100
Flat 17 (17 %)
Sessile 64 (64 %)
Pedunculated 12 (12 %)
Missing 7 (7 %)
Serrated lesions 17
Flat 1 (6 %)
Sessile 15 (88 %)
Pedunculated 1 (6 %)
Missing 0
Location of detected adenomas
Advanced adenomas 32
Rectosigmoid 15 (47 %)
Proximala 17 (53 %)
Non-advanced adenomas 100
Rectosigmoid 13 (13 %)
Proximala 84 (84 %)
Missing 3 (3 %)
Serrated lesions 17
Rectosigmoid 9 (53 %)
Proximala 7 (41 %)
Missing 1 (6 %)
Data are n(%)
a Proximal is defined as descending colon, transverse colon, ascending
colon or caecum (as Atkin [Atkin Lancet 2010])
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(Table 4) [8]. Adding the 24 surveillance participants with at
least one advanced neoplasia, the proportion of CTC partici-
pants with at least one advanced neoplasia significantly in-
creased to 84 of 982 participants (p<0.001). The overall yield
per 100 CTC participants increased from 6.1 to 8.6 (p<0.001)
and relative to those invited for CTC screening, we found an
increased yield from 2.1 to 2.9 advanced neoplasia per 100
CTC invitees (p<0.001).
Extracolonic findings
Potentially important findings (C-RADS E3 or E4) were
found in 4 (7.1 %) of 56 participants. One finding (1.8 %)
was new with respect to the initial CTC and required no fur-
ther handling after assessment by the general physician (E4;
collapsed osteoporotic vertebrae). One finding (1.8 %) was
increased in size at surveillance CTC and required the sched-
uled appointment at the urologist to be brought forward (E4,
growth of multiple angiomyolipomas).
Adverse events
No serious adverse events occurred during surveillance CTC or
subsequent OC. One individual with an OC and polypectomy
of a 20 mm pedunculated sigmoid polyp in a different hospital
prior to invitation returned after 11 days with a perforation.
Discussion
The surveillance yield for advanced neoplasia was 29.3% (24/
82). No CRC or high-grade dysplasia was detected, suggest-
ing a safe surveillance strategy. Inclusion of the surveillance
yield of 82 patients under surveillance for 6-9 mm polyps led
to a significant increase in yield of population-based CTC
screening for advanced neoplasia, both per 100 CTC partici-
pants (from 6.1 to 8.6; p<0.001) and per 100 invitees (from
2.1 to 2.9; p<0.001) [8]. The surveillance participation rate
was high (86.2 %) while new important extracolonic findings
were rarely detected (1.8 %).
To our knowledge, there has not been a previous study
reporting on the yield and participation of surveillance CTC
in the setting of an invitation-based CRC screening program.
One article has been published describing the findings of a 6-
9 mm surveillance cohort of a non-invitational primary
screening population of 303 patients [18]. In that surveillance
population of 303 patients with 6-9 mm polyps, 24 advanced
neoplasms resided in 23 patients (yield 7.6 % (23/303)) (email
correspondence PJ Pickhardt, MD; date: 19 July 2014). A
possible explanation for our higher diagnostic yield is that
we referred all patients with ≥6 mm polyps for OC and ob-
tained histopathological verification of all lesions. Instead,
that study referred only individuals with polyps with ≥1 mm
increase in size thereby excluding stable or decreasing size
≥6 mm polyps and leaving a group of individuals (n=143)
for ongoing CTC surveillance. Also, they did not present data
from patients who withdrew prior to surveillance CTC, for our
study inclusion of this data resulted in an additional nine pa-
tients with advanced adenomas. The participation rate in both
studies was comparable (80 % versus 86 %).
The high yield in our CTC surveillance population showed
that the earlier reported initial yield of screening with CTC has
been underestimated [8]. Whether the nine advanced adenomas
resulting from the preliminary OCs were more likely part of the
initial COCOS yield or the surveillance yield is debatable per-
patient given the variety in time point of the OCs (Appendix 3).
In addition, by including the seven patients with advanced
adenomas which were measured ≥10 mm by one of the
Table 4 Most advanced lesion per participant and per invitee for primary and surveillance CT colonography
Yield per 100 participants Yield per 100 invitees
COCOS
population
(n=982)
COCOS population
including surveillance
CTC (n=982)
p Value COCOS population
(n=2920)
COCOS population
including surveillance
CTC (n=2920)
p Value
Colorectal cancer (n) 0.5 (5) 0.5 (5) ns 0.2 (5) 0.2 (5) ns
Advanced adenoma (n) 5.6 (55) 8.0 (79) <0.001 1.9 (55) 2.7 (79) <0.001
≥10 mm 5.4 (53) 7.6 (75) <0.001 1.8 (53) 2.6 (75) <0.001
Non-advanced adenoma (n) 1.2 (12) 3.2 (31) <0.001 0.4 (12) 1.1 (31) <0.001
Serrated adenoma (n) 0.2 (2) 0.4 (4) ns 0.1 (2) 0.1 (4) ns
Hyperplastic polyp (n) 0.3 (3) 0.4 (4) ns 0.1 (3) 0.1 (4) ns
Advanced neoplasia (n) 6.1 (60) 8.6 (84) <0.001 2.1 (60) 2.9 (84) <0.001
≥10 mm 5.9 (58) 8.1 (80) <0.001 2.0 (58) 2.7 (80) <0.001
Note - Numbers in brackets are the actual number of individuals
Ns=not significant
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technologists in the surveillance yield, one might be compensat-
ing for initial misclassification by the radiologist. However, over-
all yield was not affected by this and is, therefore, probably the
most representative outcome of screening for CRC with CTC.
When interpreting this overall yield one should realize that
progression in growth and/or transformation from tubular to
tubulovillous histology could have taken place during the sur-
veillance interval, probably leading to a larger number of ad-
vanced adenomas. A side-by-side comparison with the initial
OC yield is therefore not possible. However, in this surveil-
lance population all referrals for OC were for polyps already
present at initial screening CTC. We believe this justifies our
strategy to add the surveillance results to the initial CTC
screening results leading to a significant increase in overall
yield per 100 participants and per 100 invitees. As surveil-
lance CTC for 6-9 mm polyps is a viable option in CRC
screening, this surveillance yield must be taken into account
when deciding on a proper screening strategy.
Debate remains regarding the policy for 6-9 mm polyps.
Supportive for referral at ≥6 mm is the considerable yield of
participants with advanced adenomas in our surveillance
population (29.3 %). On the other hand, most advanced ade-
nomas were ≥10 mm and referral at ≥10 mm with continuing
CTC surveillance for 6-9 mm polyps would have led to a
decreased number of OCs and a substantial increase of PPV
for advanced neoplasia (from 45% to 75%). Similar to another
surveillance CTC study, no interval CRC’s were detected and
none versus only one advanced adenoma with high-grade dys-
plasia in their study, suggesting a safe strategy [18]. A sigmoid-
oscopy surveillance study for <10 mm polyps also concluded
that surveillance for 6-9 mm polyps was safe [19]. In an older
population other health issues like life expectance have to be
taken into account when advising a certain screening proce-
dure. In our population the four deceased and one severely ill
invitee probably had benefit from this non-aggressive follow-
up strategy. However, the true efficacy and safety of surveil-
lance for 6-9 mm polyps awaits a study that incorporates mul-
tiple CTC follow-up studies over a longer interval.
Extracolonic findings have been mentioned as a potential
advantage as well as a disadvantage of CTC [4, 20]. To our
knowledge, there is no data on extracolonic findings in sur-
veillance populations after initial CTC screening. As expect-
ed, the prevalence of potentially important extracolonic find-
ings that precipitate additional diagnostic follow-up testing in
our surveillance population is lower than in a primary CTC
screening population (1.8 % versus 4.4 % – 11 %), as the
course of time and/or previous additional investigations have
proven some findings to be benign or treatment has taken
place [7, 8, 21–23].
Our study has some limitations. The trial from which this
surveillance population originated was powered for compar-
ing the participation rate of CTC versus OC screening and not
for evaluating CTC surveillance [10]. However, for
determining the overall yield of CTC in screening (including
surveillance) the study population is sizeable (2920 invitees
and 982 participants). Further, the present surveillance popu-
lation was already large enough to demonstrate a significant
increase in yield of CTC screening. We found a relatively low
PPV (45 %) when only considering advanced neoplasia at OC
as a true positive result, especially in comparison to the initial
trial (PPV 71 %). This is due to our different cut-off value for
which participants were referred for OC (now ≥6 mm instead
of ≥10 mm). This different cut-off value was used to learn
more about small polyps’ histology in surveillance. The
PPV for ≥6 mm polyps was very good (97 %), corresponding
to a large study investigating PPV for CTC detected polyps
[24]. Twenty participants had no ≥6mmpolyps at surveillance
CTC, which could be explained by polyp regression [18], a
false-positive initial CT or a false-negative surveillance CT.
No OCs were performed in participants with a negative CTC,
nor did we take the observations of other readers into account.
This was done for consistency purposes, as to make overall
yield calculations with the original COCOS trial possible.
Furthermore, determining accuracy was not the purpose of
this study. We did not classify serrated lesions as advanced
adenomas because of previous defined histopathology criteria
in the initial trial [8]. However, growing evidence shows the
malignant potential and the importance of these lesions [25,
26]. Including ≥10 mm serrated lesions as advanced adeno-
mas would have increased the diagnostic yield to 31 % (25/
82) [27].
The substantial yield in the CTC surveillance population
resulted in a significantly higher diagnostic yield of primary
CTC screening than previously has been reported [8]. We
were able to provide further insights into diagnostic yield,
participation, and new important extracolonic findings in sur-
veillance CTC, all of which should be taken into account
when deciding on a proper management strategy for patients
with 6-9 mm polyps detected at primary CRC screening.
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Appendix 1
Detailed explanation of OC procedure. OCs were per-
formed by experienced endoscopists (gastroenterologist,
gastroenterology resident or a trained gastroenterologist
nurse) according to the standard quality indicators defined
by the Society of Gastointestinal Endoscopy [14]. For
bowel preparation, 2 L of polyethylene electrolyte glycol
solution (Moviprep, Norgine bv, Amsterdam, the
Netherlands) was used together with 2 L of transparent
fluid, and a low-fibre diet for 2 days. Conscious sedation
(midazolam, Dormicum; Roche, Basel, Switzerland) and
analgesics (fentanyl , Fentanyl-Janssen; Janssen
Pharmaceuticals, Beerse, Belgium) were given intrave-
nously at the discretion of the participant and the
endoscopist. Hyoscine butylbromide was given intrave-
nously at the start of withdrawal of the endoscope to re-
duce colonic motility if needed. During the withdrawal of
the endoscope, starting from the caecum, segmental
unblinding was performed by a research nurse or research
fellow (CTN, TNB, IV). Of all detected lesions, morphol-
ogy, location, macroscopic aspect and size (measured with
open forceps) were noted. If possible, all detected lesions
were removed during the same procedure.
Appendix 2
Appendix 3
56 patients with polyps measuring
6-9 mm underwent surveillance 
CTC
17 patients with no 
polyps visible
3 patients with only <6  
mm polyps
24 patients with a 6-9
mm polyp
12 patients with a 10
mm polyp
7 patients with visibility
of initial polyp
10 patients with no
polyps visible
Retrospective 
evaluationa
Fig. 2 Evolution of 6–9 mm
polyps in surveillance patients on
CTC reflected by the most
advanced lesion per patient.
aretrospective evaluation of the
surveillance CTC by two of four
experienced observers
Index CTC & 
subsequent OC
Surveillance CTC & 
subsequent OC
AA
AA
0 CRC
15 AA
5 CRC
55 AA
Three year surveillance interval (9 AA)
AA
AA
AA
AA
AA
AA
AA
0 1 2 3
Fig. 3 Timeframe of nine
patients with an advanced
adenoma at preliminary OC prior
to the invitation for surveillance
CTC
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Table 5 Histology of 132 detected adenomas
Adenomas ≥10 mm
Villous 1 (3 %)
Tubulovillous 7 (24 %)
Tubular 21 (72 %)
Total 29
Adenomas 6-9 mm
Villous 0
Tubulovillous 3 (7 %)
Tubular 41 (93 %)
Total 44
Adenomas <6 mm
Villous 0
Tubulovillous 0
Tubular 59 (100 %)
Total 59
General
Total number of adenomas 100
Total number of advanced adenomas 32
Data are n (%)
None of the adenomas contained high-grade dysplasia
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